Levi Allan D, Burks S Shelby, Anderson Kim D, Dididze Marine, Khan Aisha, Dietrich W Dalton
Department of Neurological Surgery and the Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, FL, USA.
Cell Transplant. 2016;25(7):1395-403. doi: 10.3727/096368915X690198. Epub 2015 Nov 25.
Insufficient donor nerve graft material in peripheral nerve surgery remains an obstacle for successful long-distance regeneration. Schwann cells (SCs) can be isolated from adult mammalian peripheral nerve biopsies and can be grown in culture and retain their capacity to enhance peripheral nerve regeneration within tubular repair strategies in multiple animal models. Human Schwann cells (hSCs) can be isolated, expanded in number, and retain their ability to promote regeneration and myelinate axons, but have never been tested in a clinical case of peripheral nerve injury. A sural nerve biopsy and peripheral nerve tissue from the traumatized sciatic nerve stumps was obtained after Food and Drug Administration (FDA) and Institutional Review Board (IRB) approval as well as patient consent. The SCs were isolated after enzymatic digestion of the nerve and expanded with the use of heregulin β1 (0.1 µg/ml) and forskolin (15 mM). After two passages the Schwann cell isolates were combined with sural nerve grafts to repair a large sciatic nerve defect (7.5 cm) after a traumatic nerve injury. The sural nerve and the traumatized sciatic nerve ends both served as an excellent source of purified (90% and 97%, respectively) hSCs. Using ultrasound and magnetic resonance imaging (MRI) we were able to determine continuity of the nerve graft repair and the absence of tumor formation. The patient had evidence of proximal sensory recovery and definitive motor recovery distal to the repair in the distribution of the tibial and common peroneal nerve. The patient did experience an improvement in her pain scores over time. The goals of this approach were to determine the safety and clinical feasibility of implementing a new cellular repair strategy. In summary, this approach represents a novel strategy in the treatment of peripheral nerve injury and represents the first reported use of autologous cultured SCs after human peripheral nerve injury.
在周围神经手术中,供体神经移植材料不足仍然是成功进行长距离神经再生的障碍。雪旺细胞(SCs)可从成年哺乳动物的周围神经活检组织中分离出来,能够在培养中生长,并在多种动物模型的管状修复策略中保持其增强周围神经再生的能力。人雪旺细胞(hSCs)可以分离、扩增数量,并保留其促进再生和使轴突髓鞘化的能力,但从未在周围神经损伤的临床病例中进行过测试。在获得美国食品药品监督管理局(FDA)和机构审查委员会(IRB)批准以及患者同意后,获取了腓肠神经活检组织和创伤性坐骨神经残端的周围神经组织。通过酶消化神经后分离出SCs,并使用神经调节蛋白β1(0.1μg/ml)和福司可林(15mM)进行扩增。经过两代培养后,将雪旺细胞分离物与腓肠神经移植物结合,用于修复创伤性神经损伤后的大段坐骨神经缺损(7.5cm)。腓肠神经和创伤性坐骨神经末端均是纯化hSCs的优质来源(分别为90%和97%)。使用超声和磁共振成像(MRI),我们能够确定神经移植物修复的连续性以及是否存在肿瘤形成。患者在胫神经和腓总神经分布区域的修复远端有近端感觉恢复和明确的运动恢复迹象。随着时间的推移,患者的疼痛评分确实有所改善。该方法的目的是确定实施新的细胞修复策略的安全性和临床可行性。总之,这种方法代表了一种治疗周围神经损伤的新策略,也是首次报道在人类周围神经损伤后使用自体培养的SCs。